Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

Leukemia & Lymphoma
Clemens M WendtnerAsher A Chanan-Khan

Abstract

The objective of this study was to evaluate the safety and efficacy of different lenalidomide starting doses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). CLL patients were randomized to receive lenalidomide at initial doses of 5, 10, or 15 mg/d (N = 103). Doses were escalated by 5 mg every 28-d up to a maximum of 25 mg/d; dose reductions in up to 5 mg decrements were permitted. The most common grade ≥3 adverse events (AEs) were neutropenia and thrombocytopenia. Ten patients died during therapy (four deaths considered as related to lenalidomide); 12 patients experienced second primary malignancies. The most common cause for treatment discontinuation was AEs. Overall response rates were similar across arms. Progression-free survival and overall survival rates were longer in patients who escalated treatment (to 15 or 20 mg/d) versus those who did not. Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL.

References

Sep 24, 2004·British Journal of Haematology·Mitchell S Cairo, Michael Bishop
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanMyron S Czuczman
Apr 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leslie A AndritsosJohn C Byrd
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Apostolia-Maria TsimberidouMichael J Keating
Jan 9, 2010·Leukemia & Lymphoma·Taimur SherAsher Alban Chanan-Khan
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tadeusz RobakSergey I Moiseev
Jun 16, 2010·Leukemia & Lymphoma·Apostolia-Maria Tsimberidou, Michael J Keating
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Working Group
Dec 28, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier C BadouxAlessandra Ferrajoli
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
May 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Danelle F JamesThomas J Kipps

❮ Previous
Next ❯

Citations

Apr 8, 2017·Expert Opinion on Investigational Drugs·Gilad Itchaki, Jennifer R Brown
May 24, 2018·Cardiovascular & Hematological Disorders Drug Targets·Ota Fuchs
Aug 31, 2017·The Oncologist·Bruce D ChesonConstantine Tam
Mar 13, 2018·Physiological Research·V VenturiM Pospisek
Dec 15, 2020·Frontiers in Immunology·Valentina GriggioMarta Coscia
Aug 28, 2021·International Journal of Molecular Sciences·Nikolaos IoannouAlan G Ramsay

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Advances in Hematology
Agostino CortelezziGianluigi Reda
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Maria R KhouriIssa F Khouri
Journal of the Advanced Practitioner in Oncology
Susan Blumel, Jackie Broadway-Duren
© 2022 Meta ULC. All rights reserved